|
 |
 |
 |
 |
|
 |
|
|
|
|
We have seven key priorities to ensure we make the maximum contribution to sustainable
development. These are part of a broad work plan that covers our everyday activities.
| Priority |
Goal |
Progress 2007 |
|
Embedding sustainability
|
Ensure that contributing to sustainable development is part of our daily work and increases the success
of our business
|
Held our third sustainability workshop with 60 representatives from all relevant corporate and divisional functions. The focus was on sharing knowledge, and reconfirming our relevant sustainability issues and their
links to economic success
Prioritised and agreed to focus on six sustainability areas: - Innovation
capacities
- Value of Roche products and services
- Pricing and reimbursement conditions
- Access
to Roche products and services
- Relationships with stakeholders
- Being an attractive and responsible
employer
Identified key performance indicators (KPIs) for monitoring progress, and had these approved
by the Corporate Executive Committee
Included in the Corporate Knights and Innovest list of the
global 100 most sustainable companies
Reselected for the Dow Jones STOXX and World Sustainability
Indexes and the FTSE4Good Series
Moved from 26th to 12th place in a ranking of the number of SRI
funds invested in a company
Ranked as Gold Class in the Sustainability Asset Management Sustainability
Yearbook 2008
More on page 65 of our 2007 Annual Report and at www.roche.com/sus-bus_case
|
|
Access to healthcare
|
Continue to develop innovative medicines and ways to increase access to our products globally (in developed, developing and least developed countries)
|
Filed 14 new marketing applications and received 18 approvals
201,752 patients received free healthcare by taking part in phase I-IV clinical trials globally
Published details of 480 pharmaceutical clinical protocols, 23 diagnostic protocols and 162 trial results on independent website www.roche-trials.com since April 2005
70% of all affected patients living in countries eligible for no-profit Roche HIV/AIDS medicines
86% of all affected patients living in countries eligible for reduced-price Roche HIV/AIDS medicines
Almost 35,000 patients benefiting from patient assistance programmes (US only)
Signed transfer agreements with two additional manufacturers in 2007, in Ethiopia and Zimbabwe, and announced four more agreements in Bangladesh, Kenya, Tanzania and Zimbabwe in early 2008. Total of nine agreements signed to date
Hosted Technology Transfer Initiative Media Tour and Experience Exchange to raise awareness, share best practice and build additional capacity
Signed agreement with Clinton Foundation HIV/AIDS initiative to provide sustainable diagnostic solutions for early infant diagnosis in 35 resource-limited countries.
Using our innovative dried blood spot technology, began
to develop screening programmes for tuberculosis and resistant strains, and increased access to laboratory tests and HIV/AIDS
care for people living in rural areas. These programmes are available in 35 resource-limited countries
More
on pages 61 -63 of our 2007 Annual Report and at www.roche.com/sus-access_summary
|
|
Ensuring responsible business practices
|
Strengthen ethical compliance and awareness in all Roche activities
|
Forty-three alleged compliance failures reported in 2007. Of these, 29 led to corrective action, including the termination of 17 contracts of employment
Risk Management Charter developed and approved by Corporate Executive Committee
Increased accountability across the Group through formalised risk management process
Developed Compliance Officer network across all affiliates e.g. by conducting five regional workshops on behaviour in business
Completed the worldwide rollout of our Code of Conduct e-learning programme, with more than 90% of employees taking part and all new hires systematically included
Ran Behaviour in Business – Finance training for all members of the finance functions at our headquarters, and initiated training at affiliate sites
Ran additional training on our revised standard operating procedures for good marketing practice for pharmaceutical marketing employees
Established a training and compliance team within our pharmaceutical business’s global medical affairs department
Introduced an online ethics training programme for pharmaceutical development employees globally, to enable them to resolve ethical issues that arise during their work.
Thirty concerns raised with our Global Ethics Liaison Office in 2007. All were resolved and none required escalation
Amended guidelines on working with patient groups and published list of key groups on website: www.roche.com/sus_eth_pgr
100% of animal testing sites now AAALAC accredited
Developed
a 3R Awards programme for employees worldwide, to improved animal welfare
More on pages 65 -70
of our 2007 Annual Report and at www.roche.com/sus_eth
|
|
Patient safety
|
Provide highly effective medicines whose benefits exceed risks and with minimal adverse drug reactions
|
Expanded patient safety section of website to increase transparency and disclosure
Strengthened Safety Risk Management plan to emphasise safe use of Roche products and maintain positive benefit/risk profile
Held an international conference on biosimiliars in Jakarta, Indonesia. Experts and regulators attended from countries including China, Malaysia, the Philippines, Taiwan and Thailand.
Recalled Viracept in all countries where it is sold in response to reports of a strange odour, to prevent additional exposure
Began to establish registers of patients who took Viracept between March and June 2007 to monitor exposure
Began a comprehensive quality review covering all manufacturing, quality control and maintenance processes in our supply chain worldwide, for all products (QuaSar)
More on page 68 of our 2007 Annual Report and at www.roche.com/sus-patient_safety and www.roche-hiv.com
|
|
Retain and attract top talent
|
Establish programmes to retain and attract the best talent for the right job, and foster a performance culture
|
Created 3,800 new jobs
Rolled out our e-recruitment system in Germany and Asia-Pacific. Candidates can now use our careers website to search for jobs globally
Roche named one of the top 20 employers in the healthcare industry by Science magazine, for the fifth year running
Filled 2,100 positions internally and hired 2,200 talented new people using our global e-recruitment system
Re-launched our corporate secondment policy, with three employees beginning secondments in developing countries: Ethiopia, Niger and Togo
15,300 employees in 41 countries – 36% of those eligible – have purchased shares through the Roche Connect programme
145 employees participated in our senior executive development programme, Roche Engage
Successfully reorganised Roche Pharmaceutical’s R&D structure and function
More on pages 72 -77 of our 2007 Annual Report and at www.roche.com/sus_emp
|
|
Support community engagement
|
Establish programmes that build on Roche’s tradition relating to sustainable community engagement
|
More than 12,000 employees from 90 countries took part in the annual Global Roche Employee AIDS Walk, raising around 750,000 Swiss francs to support children orphaned by AIDS in Malawi.
Launched pilot workshops of expanded Genetics Education Program for secondary teachers, in partnership with Life Science Learning Center of University of Zurich and Federal Technology Institute
Ran inaugural “Roche Continents - Youth! Arts! Science!”, a week-long seminar for selected European university science and arts students, in partnership with Salzburg Festival
Through UNICEF, supported two primary schools in Malawi via Re&Act, which channels employees’ donations to worthy causes and was officially launched in early 2006
Supported the International Committee of the Red Cross Clean Water Project in sub-Saharan Africa
Corporate Policy on Donations and non-commercial Sponsorship approved by Corporate Executive Committee and introduced into the divisions
Established Community Relations Contact (CRC) network across all affiliates
More on pages 78-79 of our 2007 Annual Report and at www.roche.com/sus_csoc-resp
|
|
Safety, health and environmental protection
|
Implement action plans at all sites to achieve long-term Group goals: - Reduce accident and absence rates
- Reduce environmental impacts
- Ensure energy efficiency targets
- Reduce emissions of greenhouse gas and VOC
- Improve compliance with Roche’s SHE standards
|
Roche received the first Financial Times/Citi Private Bank Global Environmental Award for best climate strategy and results
Created the new position of Corporate Security Officer. The CSO will coordinate all security activities relating to people, sites and buildings, and aspects of data protection and product counterfeiting.
Launched a new IT-based global SHE risk inventory. This will provide a global overview of Roche’s SHE risks
Launched a new intranet-based best SHE practice database where sites can share details of incidents and good practice
Gave the Responsible Care Network Award to 10 Roche sites for the best energy conservation projects and ideas
Selected 22 winners from 9 countries in our ECOmpetition, which invites employees to suggest ”eco-projects” to improve environmental protection and reduce costs at their facility
Received no significant SHE-related fines, although one severe incident was reported. Nine operators were affected by an explosion, one of them seriously
Sadly, one of our medical representatives died in a road accident while working. This was our first fatality in 7 years
More on pages 80-85 of our 2007 Annual Report and at www.roche.com/sus_env
|
|
|
|
|
|
|
print this page